Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 47 entries
Sorted by: Best Match Show Resources per page
Copper-Catalyzed Asymmetric Hydrosilylation of β-Nitroethyl Aryl Ketones.

Organic letters

Zeng W, Tan X, Yu Y, Chen GQ, Zhang X.
PMID: 31916775
Org Lett. 2020 Feb 07;22(3):858-862. doi: 10.1021/acs.orglett.9b04339. Epub 2020 Jan 09.

A copper-catalyzed asymmetric hydrosilylation of β-nitroethyl aryl ketones has been disclosed, and the corresponding chiral alcohols could be obtained in high yields (up to 99% yield) and excellent enantioselectivities (up to 96% ee). Moreover, the reaction worked well on...

Cite
Zeng W, Tan X, Yu Y, et al. Copper-Catalyzed Asymmetric Hydrosilylation of β-Nitroethyl Aryl Ketones. Org Lett. 2020;22(3):858-862doi: 10.1021/acs.orglett.9b04339.
Zeng, W., Tan, X., Yu, Y., Chen, G. Q., & Zhang, X. (2020). Copper-Catalyzed Asymmetric Hydrosilylation of β-Nitroethyl Aryl Ketones. Organic letters, 22(3), 858-862. https://doi.org/10.1021/acs.orglett.9b04339
Zeng, Weijun, et al. "Copper-Catalyzed Asymmetric Hydrosilylation of β-Nitroethyl Aryl Ketones." Organic letters vol. 22,3 (2020): 858-862. doi: https://doi.org/10.1021/acs.orglett.9b04339
Zeng W, Tan X, Yu Y, Chen GQ, Zhang X. Copper-Catalyzed Asymmetric Hydrosilylation of β-Nitroethyl Aryl Ketones. Org Lett. 2020 Feb 07;22(3):858-862. doi: 10.1021/acs.orglett.9b04339. Epub 2020 Jan 09. PMID: 31916775.
Copy Download .nbib Format: NLM
Inhibition of Histone Demethylases LSD1 and UTX Regulates ERα Signaling in Breast Cancer.

Cancers

Benedetti R, Dell'Aversana C, De Marchi T, Rotili D, Liu NQ, Novakovic B, Boccella S, Di Maro S, Cosconati S, Baldi A, Niméus E, Schultz J, Höglund U, Maione S, Papulino C, Chianese U, Iovino F, Federico A, Mai A, Stunnenberg HG, Nebbioso A, Altucci L.
PMID: 31888209
Cancers (Basel). 2019 Dec 16;11(12). doi: 10.3390/cancers11122027.

In breast cancer, Lysine-specific demethylase-1 (LSD1) and other lysine demethylases (KDMs), such as Lysine-specific demethylase 6A also known as Ubiquitously transcribed tetratricopeptide repeat, X chromosome (UTX), are co-expressed and co-localize with estrogen receptors (ERs), suggesting the potential use of...

Cite
Benedetti R, Dell'Aversana C, De Marchi T, et al. Inhibition of Histone Demethylases LSD1 and UTX Regulates ERα Signaling in Breast Cancer. Cancers (Basel). 2019;11(12)doi: 10.3390/cancers11122027.
Benedetti, R., Dell'Aversana, C., De Marchi, T., Rotili, D., Liu, N. Q., Novakovic, B., Boccella, S., Di Maro, S., Cosconati, S., Baldi, A., Niméus, E., Schultz, J., Höglund, U., Maione, S., Papulino, C., Chianese, U., Iovino, F., Federico, A., Mai, A., Stunnenberg, H. G., Nebbioso, A., & Altucci, L. (2019). Inhibition of Histone Demethylases LSD1 and UTX Regulates ERα Signaling in Breast Cancer. Cancers, 11(12), . https://doi.org/10.3390/cancers11122027
Benedetti, Rosaria, et al. "Inhibition of Histone Demethylases LSD1 and UTX Regulates ERα Signaling in Breast Cancer." Cancers vol. 11,12 (2019). doi: https://doi.org/10.3390/cancers11122027
Benedetti R, Dell'Aversana C, De Marchi T, Rotili D, Liu NQ, Novakovic B, Boccella S, Di Maro S, Cosconati S, Baldi A, Niméus E, Schultz J, Höglund U, Maione S, Papulino C, Chianese U, Iovino F, Federico A, Mai A, Stunnenberg HG, Nebbioso A, Altucci L. Inhibition of Histone Demethylases LSD1 and UTX Regulates ERα Signaling in Breast Cancer. Cancers (Basel). 2019 Dec 16;11(12). doi: 10.3390/cancers11122027. PMID: 31888209; PMCID: PMC6966629.
Copy Download .nbib Format: NLM
Comprehensive .

ACS pharmacology & translational science

Sacilotto N, Dessanti P, Lufino MMP, Ortega A, Rodríguez-Gimeno A, Salas J, Maes T, Buesa C, Mascaró C, Soliva R.
PMID: 34927013
ACS Pharmacol Transl Sci. 2021 Nov 12;4(6):1818-1834. doi: 10.1021/acsptsci.1c00223. eCollection 2021 Dec 10.

Lysine-specific demethylase 1 (LSD1 or KDM1A) is a chromatin modifying enzyme playing a key role in the cell cycle and cell differentiation and proliferation through the demethylation of histones and nonhistone substrates. In addition to its enzymatic activity, LSD1...

Cite
Sacilotto N, Dessanti P, Lufino MMP, et al. Comprehensive . ACS Pharmacol Transl Sci. 2021;4(6):1818-1834doi: 10.1021/acsptsci.1c00223.
Sacilotto, N., Dessanti, P., Lufino, M. M. P., Ortega, A., Rodríguez-Gimeno, A., Salas, J., Maes, T., Buesa, C., Mascaró, C., & Soliva, R. (2021). Comprehensive . ACS pharmacology & translational science, 4(6), 1818-1834. https://doi.org/10.1021/acsptsci.1c00223
Sacilotto, Natalia, et al. "Comprehensive ." ACS pharmacology & translational science vol. 4,6 (2021): 1818-1834. doi: https://doi.org/10.1021/acsptsci.1c00223
Sacilotto N, Dessanti P, Lufino MMP, Ortega A, Rodríguez-Gimeno A, Salas J, Maes T, Buesa C, Mascaró C, Soliva R. Comprehensive . ACS Pharmacol Transl Sci. 2021 Nov 12;4(6):1818-1834. doi: 10.1021/acsptsci.1c00223. eCollection 2021 Dec 10. PMID: 34927013; PMCID: PMC8669716.
Copy Download .nbib Format: NLM
A combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cells.

Oncotarget

Sha S, Zhai Y, Lin C, Wang H, Chang Q, Song S, Ren M, Liu G.
PMID: 28881812
Oncotarget. 2017 Jun 07;8(32):53302-53312. doi: 10.18632/oncotarget.18396. eCollection 2017 Aug 08.

Many studies are based on the hypothesis that recurrence and drug resistance in lung carcinoma are due to a subpopulation of cancer stem-like cells (CSLCs) in solid tumors. Therefore it is crucial to screen for and recognize lung CSLCs....

Cite
Sha S, Zhai Y, Lin C, et al. A combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cells. Oncotarget. 2017;8(32):53302-53312doi: 10.18632/oncotarget.18396.
Sha, S., Zhai, Y., Lin, C., Wang, H., Chang, Q., Song, S., Ren, M., & Liu, G. (2017). A combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cells. Oncotarget, 8(32), 53302-53312. https://doi.org/10.18632/oncotarget.18396
Sha, Shuang, et al. "A combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cells." Oncotarget vol. 8,32 (2017): 53302-53312. doi: https://doi.org/10.18632/oncotarget.18396
Sha S, Zhai Y, Lin C, Wang H, Chang Q, Song S, Ren M, Liu G. A combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cells. Oncotarget. 2017 Jun 07;8(32):53302-53312. doi: 10.18632/oncotarget.18396. eCollection 2017 Aug 08. PMID: 28881812; PMCID: PMC5581111.
Copy Download .nbib Format: NLM
Histone demethylase LSD1 regulates bone mass by controlling WNT7B and BMP2 signaling in osteoblasts.

Bone research

Sun J, Ermann J, Niu N, Yan G, Yang Y, Shi Y, Zou W.
PMID: 29707403
Bone Res. 2018 Apr 26;6:14. doi: 10.1038/s41413-018-0015-x. eCollection 2018.

Multiple regulatory mechanisms control osteoblast differentiation and function to ensure unperturbed skeletal formation and remodeling. In this study we identify histone lysine-specific demethylase 1(LSD1/KDM1A) as a key epigenetic regulator of osteoblast differentiation. Knockdown of LSD1 promoted osteoblast differentiation of...

Cite
Sun J, Ermann J, Niu N, et al. Histone demethylase LSD1 regulates bone mass by controlling WNT7B and BMP2 signaling in osteoblasts. Bone Res. 2018;6:14doi: 10.1038/s41413-018-0015-x.
Sun, J., Ermann, J., Niu, N., Yan, G., Yang, Y., Shi, Y., & Zou, W. (2018). Histone demethylase LSD1 regulates bone mass by controlling WNT7B and BMP2 signaling in osteoblasts. Bone research, 614. https://doi.org/10.1038/s41413-018-0015-x
Sun, Jun, et al. "Histone demethylase LSD1 regulates bone mass by controlling WNT7B and BMP2 signaling in osteoblasts." Bone research vol. 6 (2018): 14. doi: https://doi.org/10.1038/s41413-018-0015-x
Sun J, Ermann J, Niu N, Yan G, Yang Y, Shi Y, Zou W. Histone demethylase LSD1 regulates bone mass by controlling WNT7B and BMP2 signaling in osteoblasts. Bone Res. 2018 Apr 26;6:14. doi: 10.1038/s41413-018-0015-x. eCollection 2018. PMID: 29707403; PMCID: PMC5916912.
Copy Download .nbib Format: NLM
Neurotransmitter-induced changes in arachidonate incorporation into rat brain phospholipids: pharmacological manipulations of receptors, presynaptic uptake, mao activity and deacylation-reacylation processes.

Neurochemistry international

Barkai AI, Murthy LR.
PMID: 19651087
Neurochem Int. 1988;13(3):319-26. doi: 10.1016/0197-0186(88)90004-6.

The incorporation of [(3)H]arachidonic acid ([(3)H]AA) into phospholipids (PL) of rat brain, was studied in cerebral cortex slices in the presence and absence of norepinephrine (NE), serotonin (5-HT) and carbamylcholine (CCH). Both NE and 5-HT produced a concentration-dependent effect...

Cite
Barkai AI, Murthy LR. Neurotransmitter-induced changes in arachidonate incorporation into rat brain phospholipids: pharmacological manipulations of receptors, presynaptic uptake, mao activity and deacylation-reacylation processes. Neurochem Int. 1988;13(3):319-26doi: 10.1016/0197-0186(88)90004-6.
Barkai, A. I., & Murthy, L. R. (1988). Neurotransmitter-induced changes in arachidonate incorporation into rat brain phospholipids: pharmacological manipulations of receptors, presynaptic uptake, mao activity and deacylation-reacylation processes. Neurochemistry international, 13(3), 319-26. https://doi.org/10.1016/0197-0186(88)90004-6
Barkai, A I, and Murthy, L R. "Neurotransmitter-induced changes in arachidonate incorporation into rat brain phospholipids: pharmacological manipulations of receptors, presynaptic uptake, mao activity and deacylation-reacylation processes." Neurochemistry international vol. 13,3 (1988): 319-26. doi: https://doi.org/10.1016/0197-0186(88)90004-6
Barkai AI, Murthy LR. Neurotransmitter-induced changes in arachidonate incorporation into rat brain phospholipids: pharmacological manipulations of receptors, presynaptic uptake, mao activity and deacylation-reacylation processes. Neurochem Int. 1988;13(3):319-26. doi: 10.1016/0197-0186(88)90004-6. PMID: 19651087.
Copy Download .nbib Format: NLM
The effect of tranylcypromine on noradrenergic nerve terminals in different brain regions.

Neurochemistry international

Gomez J, Fillenz M.
PMID: 20487861
Neurochem Int. 1982;4(2):135-41. doi: 10.1016/0197-0186(82)90007-9.

Synaptosomes were prepared from cerebellum, cortex, hypothalamus and hippocampus of rat brain. The noradrenaline content of synaptosomes and vesicles was assayed; the latter was measured after washing the synaptosomes with osmolizing solution. Incubating synaptosomes with [(3)H]noradrenaline under saturating conditions...

Cite
Gomez J, Fillenz M. The effect of tranylcypromine on noradrenergic nerve terminals in different brain regions. Neurochem Int. 1982;4(2):135-41doi: 10.1016/0197-0186(82)90007-9.
Gomez, J., & Fillenz, M. (1982). The effect of tranylcypromine on noradrenergic nerve terminals in different brain regions. Neurochemistry international, 4(2), 135-41. https://doi.org/10.1016/0197-0186(82)90007-9
Gomez, J, and Fillenz, M. "The effect of tranylcypromine on noradrenergic nerve terminals in different brain regions." Neurochemistry international vol. 4,2 (1982): 135-41. doi: https://doi.org/10.1016/0197-0186(82)90007-9
Gomez J, Fillenz M. The effect of tranylcypromine on noradrenergic nerve terminals in different brain regions. Neurochem Int. 1982;4(2):135-41. doi: 10.1016/0197-0186(82)90007-9. PMID: 20487861.
Copy Download .nbib Format: NLM
Age-Related Neostriatal Alterations in the Rat: Failure of L-DOPA to Alter Behavior.

Neurobiology of aging

Joseph JA, Filburn C, Tzankoff SP, Thompson JM, Engel BT.
PMID: 24279934
Neurobiol Aging. 1980;1(2):119-25. doi: 10.1016/0197-4580(80)90004-4.

Age differences in rotational behavior were examined in young (6 mo) and old (24 mo) Wistar rats lesioned in the left substantia nigra with 6-OHDA. Young animals showed a 50% increase in rotational behavior with L-DOPA pretreatment and a...

Cite
Joseph JA, Filburn C, Tzankoff SP, et al. Age-Related Neostriatal Alterations in the Rat: Failure of L-DOPA to Alter Behavior. Neurobiol Aging. 1980;1(2):119-25doi: 10.1016/0197-4580(80)90004-4.
Joseph, J. A., Filburn, C., Tzankoff, S. P., Thompson, J. M., & Engel, B. T. (1980). Age-Related Neostriatal Alterations in the Rat: Failure of L-DOPA to Alter Behavior. Neurobiology of aging, 1(2), 119-25. https://doi.org/10.1016/0197-4580(80)90004-4
Joseph, J A, et al. "Age-Related Neostriatal Alterations in the Rat: Failure of L-DOPA to Alter Behavior." Neurobiology of aging vol. 1,2 (1980): 119-25. doi: https://doi.org/10.1016/0197-4580(80)90004-4
Joseph JA, Filburn C, Tzankoff SP, Thompson JM, Engel BT. Age-Related Neostriatal Alterations in the Rat: Failure of L-DOPA to Alter Behavior. Neurobiol Aging. 1980;1(2):119-25. doi: 10.1016/0197-4580(80)90004-4. PMID: 24279934.
Copy Download .nbib Format: NLM
Correction: LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.

Leukemia

Barth J, Abou-El-Ardat K, Dalic D, Kurrle N, Maier AM, Mohr S, Schütte J, Vassen L, Greve G, Schulz-Fincke J, Schmitt M, Tosic M, Metzger E, Bug G, Khandanpour C, Wagner SA, Lübbert M, Jung M, Serve H, Schüle R, Berg T.
PMID: 30837671
Leukemia. 2019 Jun;33(6):1541. doi: 10.1038/s41375-019-0415-y.

The original version of this Article contained an error in the Acknowledgements section.

Cite
Barth J, Abou-El-Ardat K, Dalic D, et al. Correction: LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML. Leukemia. 2019;33(6):1541doi: 10.1038/s41375-019-0415-y.
Barth, J., Abou-El-Ardat, K., Dalic, D., Kurrle, N., Maier, A. M., Mohr, S., Schütte, J., Vassen, L., Greve, G., Schulz-Fincke, J., Schmitt, M., Tosic, M., Metzger, E., Bug, G., Khandanpour, C., Wagner, S. A., Lübbert, M., Jung, M., Serve, H., Schüle, R., & Berg, T. (2019). Correction: LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML. Leukemia, 33(6), 1541. https://doi.org/10.1038/s41375-019-0415-y
Barth, Jessica, et al. "Correction: LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML." Leukemia vol. 33,6 (2019): 1541. doi: https://doi.org/10.1038/s41375-019-0415-y
Barth J, Abou-El-Ardat K, Dalic D, Kurrle N, Maier AM, Mohr S, Schütte J, Vassen L, Greve G, Schulz-Fincke J, Schmitt M, Tosic M, Metzger E, Bug G, Khandanpour C, Wagner SA, Lübbert M, Jung M, Serve H, Schüle R, Berg T. Correction: LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML. Leukemia. 2019 Jun;33(6):1541. doi: 10.1038/s41375-019-0415-y. PMID: 30837671.
Copy Download .nbib Format: NLM
QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.

Anti-cancer agents in medicinal chemistry

Abdizadeh R, Heidarian E, Hadizadeh F, Abdizadeh T.
PMID: 32698753
Anticancer Agents Med Chem. 2021;21(8):987-1018. doi: 10.2174/1871520620666200721134010.

BACKGROUND: Histone Lysine Demetylases1 (LSD1) is a promising medication to treat cancer, which plays a crucial role in epigenetic modulation of gene expression. Inhibition of LSD1with small molecules has emerged as a vital mechanism to treat cancer.OBJECTIVE: In the...

Cite
Abdizadeh R, Heidarian E, Hadizadeh F, et al. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents. Anticancer Agents Med Chem. 2021;21(8):987-1018doi: 10.2174/1871520620666200721134010.
Abdizadeh, R., Heidarian, E., Hadizadeh, F., & Abdizadeh, T. (2021). QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents. Anti-cancer agents in medicinal chemistry, 21(8), 987-1018. https://doi.org/10.2174/1871520620666200721134010
Abdizadeh, Rahman, et al. "QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents." Anti-cancer agents in medicinal chemistry vol. 21,8 (2021): 987-1018. doi: https://doi.org/10.2174/1871520620666200721134010
Abdizadeh R, Heidarian E, Hadizadeh F, Abdizadeh T. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents. Anticancer Agents Med Chem. 2021;21(8):987-1018. doi: 10.2174/1871520620666200721134010. PMID: 32698753.
Copy Download .nbib Format: NLM
Tranylcypromine specificity for monoamine oxidase is limited by promiscuous protein labelling and lysosomal trapping.

RSC chemical biology

Drechsel J, Kyrousi C, Cappello S, Sieber SA.
PMID: 34458760
RSC Chem Biol. 2020 Aug 12;1(4):209-213. doi: 10.1039/d0cb00048e. eCollection 2020 Oct 01.

Monoamine oxidases MAOA and MAOB catalyze important cellular functions such as the deamination of neurotransmitters. Correspondingly, MAO inhibitors are used for the treatment of severe neuropsychiatric disorders such as depression. A commonly prescribed drug against refractory depression is tranylcypromine,...

Cite
Drechsel J, Kyrousi C, Cappello S, et al. Tranylcypromine specificity for monoamine oxidase is limited by promiscuous protein labelling and lysosomal trapping. RSC Chem Biol. 2020;1(4):209-213doi: 10.1039/d0cb00048e.
Drechsel, J., Kyrousi, C., Cappello, S., & Sieber, S. A. (2020). Tranylcypromine specificity for monoamine oxidase is limited by promiscuous protein labelling and lysosomal trapping. RSC chemical biology, 1(4), 209-213. https://doi.org/10.1039/d0cb00048e
Drechsel, Jonas, et al. "Tranylcypromine specificity for monoamine oxidase is limited by promiscuous protein labelling and lysosomal trapping." RSC chemical biology vol. 1,4 (2020): 209-213. doi: https://doi.org/10.1039/d0cb00048e
Drechsel J, Kyrousi C, Cappello S, Sieber SA. Tranylcypromine specificity for monoamine oxidase is limited by promiscuous protein labelling and lysosomal trapping. RSC Chem Biol. 2020 Aug 12;1(4):209-213. doi: 10.1039/d0cb00048e. eCollection 2020 Oct 01. PMID: 34458760; PMCID: PMC8341850.
Copy Download .nbib Format: NLM
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.

The international journal of neuropsychopharmacology

Veraart JKE, Smith-Apeldoorn SY, Bakker IM, Visser BAE, Kamphuis J, Schoevers RA, Touw DJ.
PMID: 34170315
Int J Neuropsychopharmacol. 2021 Oct 23;24(10):808-831. doi: 10.1093/ijnp/pyab039.

BACKGROUND: The use of ketamine for depression has increased rapidly in the past decades. Ketamine is often prescribed as an add-on to other drugs used in psychiatric patients, but clear information on drug-drug interactions is lacking. With this review,...

Cite
Veraart JKE, Smith-Apeldoorn SY, Bakker IM, et al. Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. Int J Neuropsychopharmacol. 2021;24(10):808-831doi: 10.1093/ijnp/pyab039.
Veraart, J. K. E., Smith-Apeldoorn, S. Y., Bakker, I. M., Visser, B. A. E., Kamphuis, J., Schoevers, R. A., & Touw, D. J. (2021). Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. The international journal of neuropsychopharmacology, 24(10), 808-831. https://doi.org/10.1093/ijnp/pyab039
Veraart, Jolien K E, et al. "Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review." The international journal of neuropsychopharmacology vol. 24,10 (2021): 808-831. doi: https://doi.org/10.1093/ijnp/pyab039
Veraart JKE, Smith-Apeldoorn SY, Bakker IM, Visser BAE, Kamphuis J, Schoevers RA, Touw DJ. Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. Int J Neuropsychopharmacol. 2021 Oct 23;24(10):808-831. doi: 10.1093/ijnp/pyab039. PMID: 34170315; PMCID: PMC8538895.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 47 entries